Connect with us

Fertility

Fairtility unveils CHLOE OQ™ expanding its offering into fertility preservation

CHLOE OQ™ secures CE, empowering embryologists and patients with oocyte quality insights for egg freezing, egg donation and IVF applications

Published

on

Fairtility's CHLOE OQ™ aims to empower embryologists and patients with oocyte quality insights for egg freezing, egg donation and IVF applications
Fairtility, the transparent AI innovator powering reproductive care for improved outcomes, has announced the launch of CHLOE OQ™, bringing Oocyte Quality Insights to CHLOE’s core technology suite of capabilities and expanding the applicability of its AI-driven decision support tool to fertility preservation.

The solution will be unveiled at the 39th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) being held in Copenhagen, Denmark from June 25 to 28, 2023.

With CE declared for CHLOE OQ™, the new Oocyte Quality Insights capability offers IVF professionals comprehensive information to support decision making as patients undergo fertility preservation or assisted reproductive journeys.

The tool delivers predictions of an oocyte’s potential to reach the blastocyst stage post-fertilisation.

“Assessing fertility potential involves understanding three factors: sperm, oocytes and embryos. We can evaluate the viability of embryos and understand sperm quality. However, assessing oocyte quality has remained a statistical gamble,” said Dr Cristina Hickman, chief clinical officer of Fairtility.

“When looking at a seemingly ‘good’ oocyte, we can’t really identify which one will become a blast after fertilisation. CHLOE OQ helps us fill the critical gap, providing evidence-based viability predictions for the evaluation of oocytes.

“This will help clinicians to provide transparency to patients while discussing a failed IVF cycle in fertility preservation, or when assessing and allocating donor eggs.”

Oocyte quality assessment commonly relies on statistical methods based on a woman’s age. Embryologists analyse oocyte quality based on oocyte maturity and characteristics including size, texture, shape, discoloration and fragmentation.

However, these factors have proven to be subjective and lack correlation with the actual quality of the egg.

CHLOE OQ brings the power of AI to oocyte assessment, replacing generalised decision-making with personalised, data-driven AI analysis that reveals the potential of each oocyte backed by biological data.

CHLOE OQ offers personalised data to support decision making for three key applications:

  • Egg freezing: In the process of fertility preservation, IVF professionals may recommend an additional oocyte retrieval based on the raw number of oocytes retrieved. While CHLOE OQ cannot change the biology of the egg, it can assist in providing a personalised assessment and managing expectations for family planning early on. CHLOE OQ helps IVF professionals and patients make informed decisions on whether to undergo an additional oocyte retrieval cycle. The tool is designed to optimise the chances of successful IVF in the future and gives women greater control of their reproductive opportunities later in life.
  • Egg donation: CHLOE OQ helps fertility clinics and egg banks to further assess the quality of donor eggs, ensuring equitable distribution to recipients. By leveraging data-driven insights, donor-egg providers may match recipients with the most suitable donor eggs, increasing the chances of successful IVF outcomes, maximising limited donor egg resources and enhancing the donor-recipient experience.
  • IVF treatment: During IVF, older patients are often guided to utilise donor eggs based on age rather than the true quality of their eggs. At 40-years of age, approximately 10 per cent of patients utilise their own eggs, and by 44-years old, this number drops to one per cent. CHLOE OQ is expected to help IVF professionals consider if a patient’s own eggs have sufficient quality for a successful IVF treatment, or if an egg donor may be a more suitable option. This reduces costs for patients undergoing IVF and maximises egg donor resources. A better understanding of oocyte quality also provides IVF professionals insight on an oocyte’s role in a failed IVF cycle, enabling better treatment decisions for future IVF cycles.

“Adding oocyte analysis broadens CHLOE’s core technology capabilities, extending beyond embryo assessment for IVF. CHLOE OQ now provides decision support for fertility preservation, egg donation, and female-factor infertility in IVF treatment. This expansion allows us to assist a larger population seeking to secure their reproductive futures,” stated Eran Eshed, CEO and co-Founder of Fairtility.

“While we can’t halt the passage of time and the consequent decline in oocyte quality, we can effectively freeze it. With CHLOE OQ, patients, through their fertility care team, can gain transparency into their oocytes’ viability, enabling proactive management of their reproductive health and facilitating well-informed decisions based on biological data.”

CHLOE’s core technology is the first and only decision support tool that combines AI-driven analysis of embryos and oocytes with explainable biological insights in terms that IVF professionals understand and can trust.

This supports data-driven and consistent decision-making in the IVF lab, with a goal of optimising outcomes, making fertility care more efficient and creating new family-building possibilities.

Fertility

Maven Clinic launches programme for couples struggling to conceive

The programme aims to address the gap between trying to conceive and fertility treatment

Published

on

The US virtual clinic Maven has launched a health coaching programme in an effort to expand family-building options for couples struggling to conceive.

With 86 per cent of women not receiving preconception care from their family physician or OB/GYN, Maven’s Trying-To-Conceive (TTC) health coaching programme aims to support people who may be struggling and want to get pregnant without IVF.

The programme includes one-to-one support, reproductive education, ovulation tracking kits, as well as referrals to resources for mental health and nutrition.

“Maven is making sure every family can access the shortest pathway to having a healthy baby,” said Kate Ryder, Maven Clinic founder and CEO.

“We have constructed a unique model that, for the first time, aligns incentives among the stakeholders in healthcare to support people who are trying to conceive.”

To address the gap between trying to conceive and fertility treatment, Maven’s TTC Coaching service brings the benefits of health coaching to fertility care, providing members with “personalised” support and reproductive education, Ryder said. 

Dr Neel Shah, Maven Clinic’s chief medical officer, added: “While most sex education is spent teaching people how to avoid pregnancy, very little time is invested in empowering them with the guidance needed to become pregnant when they’re ready.

“Our coaching program supports couples to understand why they are struggling to conceive and in many cases helps them get pregnant without needing IVF.”

Further product enhancements the Maven team has announced include the Maven Managed Benefit platform, as well as an expansion of the company’s reproductive urology provider network for male fertility support.

To receive the Femtech World newsletter, sign up here.

Continue Reading

News

Brazilian fertility network FertGroup partners with Future Fertility to launch innovative oocyte assessment software across all clinics

The collaboration marks a significant milestone in advancing fertility care in Brazil

Published

on

FertGroup Medicina Reproductiva, a dynamic network of fertility clinics in Brazil, is proud to announce its partnership with Future Fertility to introduce cutting-edge oocyte assessment software, VIOLET™ and MAGENTA™, across its expanding network of clinics.

With nine clinics currently under FertGroup ownership, the network is poised for significant growth, aiming to surpass 15 clinics within the coming year.

This expansion is a response to the escalating demand for fertility services in Brazil, a market that has seen remarkable growth (17.6 per cent CAGR compared to the global average of ~10 per cent).

Factors driving this growth include an underserved market, rising medical tourism, and evolving population dynamics emphasising the need for advanced fertility solutions.

Led by private equity investors XP Private Equity fund, FertGroup is committed to revolutionising the fertility care landscape in Brazil and beyond.

Future Fertility is the first and only AI company to offer a comprehensive and easily integratable solution to oocyte assessment for clinics around the world.

With the world’s largest oocyte dataset, the use of this software (VIOLET™ and MAGENTA™) is at the forefront of this partnership, enabling clinicians, embryologists and patients to gain broad access to AI-driven insights about oocyte quality.

Nelson Guerreiro Pestana, CEO of FertGroup Medicina Reproductiva, highlighted the importance of integrating such innovative technologies: “At FertGroup, we are committed to bringing forward medical innovation that directly benefits the lives of Brazilians.

“Partnering with Future Fertility reinforces our market-leading position and reputation for excellence in fertility care.”

This technology optimises decisions regarding oocyte cryopreservation, ICSI IVF treatment approaches and oocyte donation. It also empowers patients by offering valuable insights into how their health status impacts expected fertility outcomes, helping clinics differentiate their service offering and provide a more patient-centric approach to fertility care.

Christy Prada, CEO of Future Fertility, expressed excitement about the expansion into the Brazilian market: “We are thrilled to partner with FertGroup Medicina Reproductiva in introducing Future Fertility’s innovative oocyte assessment software to Brazil.

“FertGroup is leading the market as the first network in Brazil to implement this technology, marking a significant step forward for fertility care in the region.”

Dr Edson Borges Jr, chief medical officer of FertGroup Medicina Reproductiva, emphasised the significance of oocyte quality in care delivery: “As a scientific leader in the field, we believe in bringing cutting edge technology to our patients, and supporting further research into new approaches to measuring and assessing progress in fertility treatment.

“Oocyte quality is a critical aspect of fertility care, and we believe that by integrating Future Fertility’s advanced tools into our care models we will advance the science in this space and demonstrate the value of leveraging oocyte quality in decision making.”

“Integrating the Future Fertility technology into our labs has been completely seamless” remarked Maria Cecilia Cardoso, group lab director.

“We already can see the value of the workflow integration, and this was a major decision factor for us. We are excited to see the benefits this will bring to decision making, providing an objective and personalised view of quality control into the process.”

This collaboration between FertGroup Medicina Reproductiva and Future Fertility marks a significant milestone in advancing fertility care in Brazil.

The introduction of VIOLET™ and MAGENTA™ software underscores FertGroup’s dedication to innovation and patient-centric care, solidifying its position as a pioneer in the Brazilian fertility market.

Continue Reading

News

Don’t politicise fertility, leaders warn after MP’s ‘patronising’ intervention

It is worrying to see a “deeply personal” women’s health issue being debated by politicians, fertility benefits providers told Femtech World

Published

on

UK femtech leaders have warned of the dangers of playing politics with fertility services following what they call “unhelpful, patronising and disrespectful” comments from an MP. 

The Conservative MP Miriam Cates raised concerns this week that women are being exploited into freezing their eggs, claiming that “most hopeful mothers are sold a lie”.

She said she fears women are being given “false promises” by large corporations offering them money to freeze their eggs to put off having children to a later age.

However, reproductive benefits providers labelled the comments as “unhelpful, patronising and disrespectful”.

Eileen Burbidge MBE, executive director at reproductive health start-up Fertifa, said: “Policymakers should absolutely be giving more attention to protecting reproductive health access and treatment options for women, given how shamefully ignored women’s health has been for too long.

“However, characterising egg freezing in the way that Miriam Cates has recently done is unhelpful, patronising and disrespectful to women who rely upon the option to freeze their eggs whether for medical reasons, to donate to others who suffer from infertility or for their own future optionality to relieve patriarchal societal pressures of finding a life partner or starting a family.”

Far from being exploitative, employers who offer financial and wellbeing access to reproductive healthcare are responding to what their talent is asking for, Burbidge, who served on former British prime minister David Cameron’s Business Advisory Group, told Femtech World.

“Data has consistently shown that women do not choose to freeze their eggs in order to work longer or prioritise their careers, but rather because they’ve yet to find a life partner and wish to not succumb to patriarchal societal pressures to do so.

“The fact that companies are supporting this will hopefully mean more women recognise the fact that the likelihood of success increases the earlier they freeze their eggs.”

Leila Thabet, UK general manager at Maven Clinic, said it is concerning to see a highly emotionally charged women’s health issue being debated by politicians and commentators with their own agendas.

“It is correct that egg freezing will not work for all women, but rather than paint an entirely bleak picture of the practice, it is vital that we empower women with facts around the procedure so they do not fall prey to exploitative clinics and operators who may not have their best interests at heart,” she said.

“At a time when data shows that women’s health care needs are still largely being neglected, it is unhelpful to dismiss the provision of women’s and family health benefits in the workplace as exploitative. This is as unhelpful as it is untrue.”

Jenny Saft, co-founder and CEO of fertility benefits provider Apryl, said there is a misconception that fertility benefits platforms offer egg freezing to keep women in the workplace.

“This is not how these programmes are designed or implemented. From my experience, it’s rare to find a company that limits its fertility benefits to egg freezing alone,” she explained.

“Typically, employers provide a comprehensive suite of fertility and family-forming options, including but not limited to egg freezing, sperm freezing, IVF, adoption, and surrogacy.”

Egg freezing has seen a sharp rise in the UK. More women than ever before are undergoing procedures, with egg and embryo freezing now the fastest growing fertility treatments in the country.

According to the Human Fertilisation and Embryology Authority (HEFA), egg freezing and storage saw a 64 per cent increase in 2021 compared to 2019.

The procedure, which is not available on the NHS, is largely carried out by private clinics at a price tag of £7,000 to £8,000. Fertility benefits platforms claim to provide financial and emotional support for egg freezing, giving women more freedom over when to start a family.

“When egg freezing is offered as an employee benefit it takes away the financial burden of egg freezing,” said Dr Catherine Hill, head of policy and public affairs at Fertility Network UK.

“However, it does not remove the health risks and side effects associated with the invasive medical process, or the emotionally demanding and often upsetting nature of freezing your eggs – all of which women need to consider before making any decision.

“Because this is such a big life choice, it is vital women do not feel under any obligation from their employer to take advantage of this employee benefit.”

Although the procedure enables some women to delay motherhood until the time that is right for them, egg freezing should never be seen as a fertility insurance policy, Hill said.

She added: “Making a decision on the right time to approach parenthood or to attempt to postpone it is a very individual commitment and must be made without pressure from anyone else, including employers. Egg freezing should be about widening women’s reproductive choices on when to have a baby, not enabling a scenario where women feel forced to delay motherhood.”

Becky Kearns, co-founder of Fertility Matters at Work, said it is crucial that companies educate employees and empower them to make informed choices.

“While egg freezing will be seen as a huge benefit and attraction for the next generation of workforce, it needs to be balanced with information and facts to allow people to make informed choices,” she told Femtech World.

“Organisations should be supporting fertility treatment as a whole where possible, not just for those early in their careers. If the focus is solely on egg freezing there’s the risk that this may be perceived as a means to encourage employees to delay having a family, to the short-term benefit of the employer.

“This benefit on its own, without balanced information and education about outcomes and overall fertility awareness, may result in people purposely delaying having children, thinking they have a guarantee for when the time is right, when in reality it gives them a chance.

Miriam Cates has been approached for comment.

To receive the Femtech World newsletter, sign up here.

Continue Reading

Trending

Copyright © 2023 Aspect Publishing Ltd. All Rights Reserved.